AU2006254395B2 - Ergoline derivatives and their use as chemokine receptor ligands - Google Patents

Ergoline derivatives and their use as chemokine receptor ligands Download PDF

Info

Publication number
AU2006254395B2
AU2006254395B2 AU2006254395A AU2006254395A AU2006254395B2 AU 2006254395 B2 AU2006254395 B2 AU 2006254395B2 AU 2006254395 A AU2006254395 A AU 2006254395A AU 2006254395 A AU2006254395 A AU 2006254395A AU 2006254395 B2 AU2006254395 B2 AU 2006254395B2
Authority
AU
Australia
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
optionally
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006254395A
Other languages
English (en)
Other versions
AU2006254395A1 (en
Inventor
Rolf Baenteli
Fraser Glickman
Jiri Kovarik
Ian Lewis
Markus Streiff
Gebhard Thoma
Hans-Gunter Zerwes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006254395A1 publication Critical patent/AU2006254395A1/en
Application granted granted Critical
Publication of AU2006254395B2 publication Critical patent/AU2006254395B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
AU2006254395A 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands Ceased AU2006254395B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0511060.6A GB0511060D0 (en) 2005-05-31 2005-05-31 Organic compounds
GB0511060.6 2005-05-31
PCT/EP2006/005106 WO2006128658A1 (en) 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands

Publications (2)

Publication Number Publication Date
AU2006254395A1 AU2006254395A1 (en) 2006-12-07
AU2006254395B2 true AU2006254395B2 (en) 2010-09-09

Family

ID=34834898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006254395A Ceased AU2006254395B2 (en) 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands

Country Status (12)

Country Link
US (1) US7666877B2 (enExample)
EP (1) EP1893611A1 (enExample)
JP (1) JP5121703B2 (enExample)
KR (1) KR20080013971A (enExample)
CN (1) CN101184754B (enExample)
AU (1) AU2006254395B2 (enExample)
BR (1) BRPI0611489A2 (enExample)
CA (1) CA2608702C (enExample)
GB (1) GB0511060D0 (enExample)
MX (1) MX2007015084A (enExample)
RU (1) RU2416613C2 (enExample)
WO (1) WO2006128658A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
JP5874124B2 (ja) 2010-06-28 2016-03-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 緑内障の処置に使用するための薬学的組成物
CA2838991A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
AU2012382929A1 (en) * 2012-06-22 2015-02-05 Map Pharmaceuticals, Inc. Novel cabergoline derivatives
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
AU2016209490B2 (en) 2015-01-20 2020-09-03 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2022232093A1 (en) 2021-04-30 2022-11-03 Mind Medicine, Inc. Lsd salt crystal forms
AU2022331317B2 (en) 2021-08-19 2025-09-11 Definium Therapeutics US, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nakahara, Y. et al., Chem. Pharm. Bull., 1971, 19, 2337-2341 *

Also Published As

Publication number Publication date
RU2007147597A (ru) 2009-07-20
CA2608702A1 (en) 2006-12-07
EP1893611A1 (en) 2008-03-05
MX2007015084A (es) 2008-01-17
BRPI0611489A2 (pt) 2010-11-23
JP5121703B2 (ja) 2013-01-16
RU2416613C2 (ru) 2011-04-20
WO2006128658A1 (en) 2006-12-07
CA2608702C (en) 2013-10-15
KR20080013971A (ko) 2008-02-13
GB0511060D0 (en) 2005-07-06
JP2008545725A (ja) 2008-12-18
CN101184754B (zh) 2010-12-22
US20090018127A1 (en) 2009-01-15
US7666877B2 (en) 2010-02-23
CN101184754A (zh) 2008-05-21
AU2006254395A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AU2006254395B2 (en) Ergoline derivatives and their use as chemokine receptor ligands
EP0712408B1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
JP2906654B2 (ja) 免疫抑制剤及びその製造方法
BR112013032415B1 (pt) Processos para preparar compostos e compostos
NZ240993A (en) 3,7-disubstituted indoles and analogues and pharmaceutical compositions
KR20030087066A (ko) 비피페리디닐-유도체 및 이의 케모킨 수용체 억제제로서의용도
SK160899A3 (en) Ergoline derivatives and their use as somatostatin receptor antagonists
GB2203431A (en) Psychotropic bicyclic imides
AU2023338045A1 (en) Inhibitors of enl/af9 yeats and flt3
EP0743944A1 (en) Azacyclic derivatives
RU2047614C1 (ru) Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
Portoghese et al. Opioid agonist and antagonist activities of morphindoles related to naltrindole
PT100658A (pt) Derivados de hidro-isoquinolina e processo para a sua preparacao
AU707861B2 (en) 3-beta-aminoazabicyclo-octane or -nonane naphthamide derivatives as antipsychotic agents
US20040067959A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists
WO2024081961A2 (en) Ester analogs of psilocin, processes for the preparation thereof, and methods of use
Doisy et al. Synthesis and benzodiazepine receptor (ω receptor) affinities of 3-substituted derivatives of pyrrolo [2, 3-c] pyridine-5-carboxylate, a novel class of ω1 selective ligands
HUT70557A (en) N,n'-disubstituted amine derivative, pharmaceutical compositions containing them and process for producing the compounds and the compositions
KUROITA et al. Synthesis and structure-activity relationships of 2, 3-dihydrobenzofuran-7-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists
CY1432A (en) Ergotalkaloids
CN121494852A (zh) 用于抗乳腺癌的四氢吡咯衍生物及其制备方法、应用及药物
GB2075973A (en) Indoloquinolizines
HK1011359B (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired